Icandra: Uses, Dosage & Side Effects

What Is Icandra and What Is It Used For?

Icandra is a fixed-dose combination (FDC) medication that brings together two well-established antidiabetic agents in a single film-coated tablet. The first active ingredient, vildagliptin, belongs to the pharmacological class known as dipeptidyl peptidase-4 (DPP-4) inhibitors, sometimes referred to as “gliptins.” The second active ingredient, metformin hydrochloride, is a member of the biguanide class and is widely regarded as the first-line pharmacological treatment for type 2 diabetes mellitus according to guidelines from the American Diabetes Association (ADA), the European Association for the Study of Diabetes (EASD), and the World Health Organization (WHO).

Type 2 diabetes mellitus is a chronic metabolic disorder characterized by insulin resistance and progressive beta-cell dysfunction, leading to elevated blood glucose levels (hyperglycemia). Over time, sustained hyperglycemia can damage blood vessels and nerves throughout the body, contributing to serious complications including cardiovascular disease, chronic kidney disease, retinopathy (eye damage), neuropathy (nerve damage), and impaired wound healing. Effective glycemic control is therefore essential to reducing the long-term risk of these complications. Large-scale clinical trials such as the United Kingdom Prospective Diabetes Study (UKPDS) and the Action in Diabetes and Vascular Disease (ADVANCE) trial have demonstrated that improving blood glucose control significantly reduces microvascular complications and, in the long term, may also reduce macrovascular events.

Vildagliptin works by inhibiting the enzyme dipeptidyl peptidase-4 (DPP-4), which is responsible for the rapid degradation of two key incretin hormones: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These incretins are released from the gut after eating and play a central role in glucose homeostasis. GLP-1, in particular, stimulates insulin secretion from pancreatic beta cells and suppresses glucagon secretion from alpha cells, both in a glucose-dependent manner. This means that the incretin effect is strongest when blood glucose levels are elevated and diminishes as glucose returns to normal, which accounts for the low hypoglycemia risk associated with DPP-4 inhibitors used as monotherapy or in combination with metformin alone. By blocking DPP-4, vildagliptin prolongs the activity of endogenous GLP-1 and GIP, effectively amplifying the body’s natural insulin response to food intake.

Metformin exerts its glucose-lowering effects through several complementary mechanisms. Its primary action is to reduce hepatic glucose production by suppressing gluconeogenesis and, to a lesser extent, glycogenolysis. Metformin also enhances insulin sensitivity in peripheral tissues (particularly skeletal muscle), promoting glucose uptake and utilization. Additionally, metformin delays intestinal absorption of glucose and has been shown to improve lipid profiles in some patients. Unlike sulfonylureas, metformin does not stimulate insulin secretion directly and therefore does not cause hypoglycemia when used alone. Metformin has been used clinically since the 1950s and is included on the WHO Model List of Essential Medicines as a core treatment for type 2 diabetes.

The rationale for combining vildagliptin and metformin in a single tablet is based on their complementary and synergistic mechanisms of action. While metformin addresses hepatic glucose overproduction and peripheral insulin resistance, vildagliptin enhances the incretin-mediated insulin response to meals. Clinical trials have demonstrated that the combination of vildagliptin and metformin produces significantly greater reductions in glycated hemoglobin (HbA1c) compared with either agent alone. In a pivotal 24-week randomized controlled trial, the addition of vildagliptin 50 mg twice daily to ongoing metformin therapy resulted in a placebo-corrected reduction in HbA1c of approximately 0.7–1.1 percentage points. Furthermore, the combination was associated with a low incidence of hypoglycemia and was generally weight-neutral, meaning that patients did not experience significant weight gain.

Icandra is indicated for the treatment of type 2 diabetes mellitus in adults, specifically in the following clinical situations:

• Add-on to metformin: For patients whose blood glucose is inadequately controlled by metformin alone at the maximally tolerated dose, in conjunction with diet and exercise.
• Combination with a sulfonylurea and metformin: As part of triple oral therapy when dual therapy with metformin and a sulfonylurea does not achieve adequate glycemic control.
• Switch from separate tablets: For patients who are already being treated with the combination of vildagliptin and metformin as individual tablets, to simplify the treatment regimen and improve adherence.
• Combination with insulin: In patients who require insulin alongside oral antidiabetic medication, Icandra can be used as the oral component when metformin alone is insufficient.

What Should You Know Before Taking Icandra?

Contraindications

Icandra must not be used in the following situations:

• Hypersensitivity: Known allergy to vildagliptin, metformin hydrochloride, or any of the excipients in the formulation.
• Diabetic ketoacidosis or diabetic precoma: These are acute complications of diabetes that require insulin treatment, not oral antidiabetic therapy.
• Severe renal impairment: Estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m². Metformin accumulates when kidney function is severely impaired, significantly increasing the risk of lactic acidosis.
• Acute conditions that may impair renal function: Including dehydration, severe infection, shock, and intravascular administration of iodinated contrast agents.
• Acute or chronic conditions causing tissue hypoxia: Such as cardiac or respiratory failure, recent myocardial infarction, and severe peripheral vascular disease, where there is a risk of lactic acidosis.
• Hepatic impairment: Including patients with elevated liver enzymes (ALT or AST greater than 3 times the upper limit of normal).
• Acute alcohol intoxication or alcoholism: Alcohol potentiates the effect of metformin on lactate metabolism.

Warnings and Precautions

Several important precautions should be discussed with your doctor before starting Icandra:

• Kidney function monitoring: Renal function (eGFR) should be assessed before initiating treatment and at least once a year thereafter. In patients with moderate renal impairment (eGFR 30–44 mL/min), the risk-benefit ratio should be carefully evaluated, and the dose of metformin may need to be reduced. More frequent monitoring (every 3–6 months) is recommended for patients at increased risk of renal deterioration, including elderly patients.
• Liver function monitoring: Rare cases of hepatic dysfunction, including hepatitis, have been reported with vildagliptin. Liver function tests (including transaminases) should be performed before starting treatment and periodically during the first year. If transaminases are found to be elevated, the finding should be confirmed with a repeat test, and Icandra should be discontinued if elevations persist at more than 3 times the upper limit of normal.
• Surgical procedures: Icandra must be discontinued at the time of surgery under general, spinal, or epidural anesthesia. Therapy should not be restarted until at least 48 hours after the procedure and only after renal function has been re-evaluated and found to be stable.
• Iodinated contrast media: Intravascular administration of iodinated contrast agents can lead to contrast-induced nephropathy, which in combination with metformin may cause lactic acidosis. Icandra must be stopped before or at the time of the imaging procedure and not restarted until at least 48 hours afterwards, provided that renal function has been re-assessed and found to be acceptable.
• Heart failure: Limited clinical experience exists with vildagliptin in patients with New York Heart Association (NYHA) class III–IV heart failure. Caution is advised in these patients.
• Pancreatitis: Cases of acute pancreatitis have been reported in patients taking DPP-4 inhibitors. Patients should be informed of the characteristic symptoms of acute pancreatitis (persistent, severe abdominal pain radiating to the back). If pancreatitis is suspected, Icandra should be discontinued immediately.
• Skin reactions: Cases of bullous pemphigoid have been reported with DPP-4 inhibitors, including vildagliptin. If bullous pemphigoid is suspected, Icandra should be discontinued.

Pregnancy and Breastfeeding

Icandra should not be used during pregnancy. There are no adequate and well-controlled clinical studies of vildagliptin in pregnant women. Animal reproductive studies at high doses have demonstrated developmental toxicity. Metformin crosses the placenta, and although some observational data exist suggesting potential safety, controlled data are limited. For women with type 2 diabetes who become pregnant or plan to become pregnant, insulin is the recommended treatment to maintain blood glucose as close to normal as possible, in order to reduce the risk of adverse outcomes for both mother and child. If you discover you are pregnant while taking Icandra, discontinue the medication and consult your doctor promptly for transition to insulin therapy.

Icandra should not be used during breastfeeding. Studies in animals have shown that both vildagliptin and metformin are excreted in milk. It is not known whether vildagliptin is excreted in human breast milk. Metformin is known to pass into human breast milk in small amounts. A risk to the nursing infant cannot be excluded, and a decision should be made whether to discontinue breastfeeding or discontinue Icandra therapy, taking into account the importance of the medication for the mother.

Children and Adolescents

Icandra is not recommended for use in children and adolescents under 18 years of age. The safety and efficacy of the vildagliptin/metformin combination have not been established in this age group. Type 2 diabetes management in pediatric patients requires specialized approaches, and healthcare providers should consider alternatives that have been studied in younger populations.

Driving and Operating Machinery

No studies on the effects of Icandra on the ability to drive and use machines have been performed. However, patients should be made aware of the risk of dizziness, which has been reported as a side effect. If you experience dizziness while taking Icandra, you should not drive or operate machinery until the symptom resolves. The risk of hypoglycemia is increased when Icandra is used in combination with a sulfonylurea or insulin, and patients should be counseled about the symptoms of low blood sugar and its potential impact on driving safety.

How Does Icandra Interact with Other Drugs?

Understanding drug interactions is critical for the safe use of Icandra, particularly because the metformin component is renally excreted and its accumulation can lead to the rare but serious complication of lactic acidosis. While vildagliptin itself has relatively few clinically significant pharmacokinetic interactions, the combination product must be considered as a whole when evaluating potential drug interactions.

Vildagliptin is not a substrate, inhibitor, or inducer of cytochrome P450 (CYP) enzymes to a clinically relevant extent. Its primary metabolic pathway involves hydrolysis by esterases rather than CYP-mediated metabolism. In dedicated drug interaction studies, vildagliptin did not affect the pharmacokinetics of commonly co-administered medications including metformin, glyburide, pioglitazone, digoxin, warfarin, amlodipine, valsartan, simvastatin, or ramipril. Similarly, these medications did not significantly alter the pharmacokinetics of vildagliptin.

Metformin, however, has several important drug interactions that must be considered. Because metformin is eliminated almost entirely by renal tubular secretion, any drug that competes for renal tubular transport or that impairs renal function can increase metformin exposure and raise the risk of lactic acidosis. The table below summarizes the most important interactions to be aware of:

It is important to note that the above list is not exhaustive. Always inform your doctor, pharmacist, or nurse about all medications you are taking, including prescription drugs, over-the-counter medications, vitamins, and herbal supplements. Some herbal products (such as St. John’s wort) and dietary supplements can also affect blood glucose levels or interact with diabetes medications.

Patients who require non-steroidal anti-inflammatory drugs (NSAIDs) should be aware that these agents can impair renal function, particularly in elderly or dehydrated patients, which may indirectly increase the risk of metformin accumulation. Short courses of NSAIDs at standard doses are generally acceptable, but prolonged use should prompt more frequent monitoring of kidney function.

What Is the Correct Dosage of Icandra?

Icandra should always be used exactly as your doctor has instructed. The dose is individualized based on your current treatment regimen, kidney function, glycemic response, and tolerability. Taking the tablets with or immediately after meals helps reduce the gastrointestinal side effects commonly associated with metformin.

Adults

The recommended dosing of Icandra depends on the patient’s current diabetes treatment. The available strength of Icandra is 50 mg vildagliptin / 850 mg metformin per tablet. The standard approach is as follows:

The maximum recommended daily dose of vildagliptin is 100 mg (i.e., 50 mg twice daily). Patients starting Icandra should ideally already be tolerating their current metformin dose, as gastrointestinal side effects are most common during the initiation period of metformin therapy. If switching from separate tablets to the fixed-dose combination, the dose of each component should be matched as closely as possible to what the patient was already receiving.

Children and Adolescents

Icandra is not recommended for use in patients under 18 years of age. There are no clinical data supporting the safety and efficacy of vildagliptin/metformin combination therapy in pediatric patients. Type 2 diabetes in children and adolescents should be managed under the guidance of a pediatric endocrinologist using treatments that have been specifically studied in younger populations.

Elderly Patients

No specific dose adjustment is required based on age alone. However, because renal function frequently declines with age, the metformin dose should be adjusted according to kidney function (eGFR). Elderly patients should have their renal function monitored more frequently, ideally every 3–6 months. The dose should be carefully titrated in elderly patients to balance efficacy with the increased risk of adverse effects, including lactic acidosis. Particular attention should be paid to hydration status, as dehydration can further impair renal function in older adults.

Renal Impairment

Missed Dose

If you forget to take a dose of Icandra, take it as soon as you remember, provided it is not almost time for your next scheduled dose. In that case, skip the missed dose entirely and take the next dose at its usual time with a meal. Never take a double dose to make up for a forgotten one, as this increases the risk of gastrointestinal side effects and could lead to hypoglycemia if you are also taking a sulfonylurea or insulin. If you frequently forget doses, consider setting a daily alarm or using a pill organizer to help with adherence.

Overdose

If you suspect that you or someone else has taken too much Icandra, seek immediate medical attention. The most serious concern with overdose is lactic acidosis due to metformin accumulation. Symptoms of lactic acidosis include nausea, vomiting, abdominal pain, rapid or labored breathing, muscle cramps, unusual fatigue, and a feeling of being cold (hypothermia). Lactic acidosis is a medical emergency that requires hospital treatment. Metformin can be removed by hemodialysis (with a clearance of up to 170 mL/min under good hemodynamic conditions), making this the most effective method for eliminating excess drug. Vildagliptin has been well tolerated in clinical studies at doses of up to 400 mg, and no specific antidote exists; treatment of vildagliptin overdose is supportive.

What Are the Side Effects of Icandra?

Like all medicines, Icandra can cause side effects, although not everybody gets them. The side effect profile of Icandra reflects the known safety profiles of its two individual components, vildagliptin and metformin. The majority of reported side effects are mild to moderate in severity and tend to improve or resolve with continued treatment. The gastrointestinal side effects attributable to metformin are the most commonly encountered and can often be minimized by taking the medication with food and by gradual dose titration when first starting metformin therapy.

Clinical trial data from the vildagliptin development program (including more than 13,000 patients), post-marketing surveillance, and the extensive global experience with metformin form the basis of the known safety profile. Below are the side effects categorized by frequency of occurrence:

The gastrointestinal side effects (nausea, vomiting, diarrhea, abdominal pain, and loss of appetite) are the most frequently reported with Icandra and are primarily attributable to the metformin component. These effects are most common during the first weeks of treatment and typically diminish with continued use. Taking Icandra with or immediately after meals significantly reduces the occurrence and severity of these symptoms. If gastrointestinal symptoms are persistent and bothersome, a temporary dose reduction may be helpful, followed by gradual re-titration.

Liver-related side effects are associated with the vildagliptin component. Asymptomatic elevations in liver transaminases (ALT, AST) have been reported, usually mild and reversible upon discontinuation. More serious hepatic events including hepatitis are rare. Routine liver function monitoring is recommended during the first year of treatment. If you develop unexplained symptoms such as persistent nausea, dark urine, jaundice (yellowing of the skin or eyes), or right upper abdominal pain, seek medical attention promptly.

Hypoglycemia (low blood sugar) is uncommon with Icandra when used without a sulfonylurea or insulin. This is because vildagliptin stimulates insulin release only when blood glucose is elevated (glucose-dependent mechanism). However, when Icandra is combined with a sulfonylurea or insulin, the risk of hypoglycemia increases, and a lower dose of the sulfonylurea or insulin may be necessary. Symptoms of hypoglycemia include sweating, trembling, rapid heartbeat, hunger, blurred vision, confusion, and difficulty concentrating.

Long-term use of metformin has been associated with decreased absorption of vitamin B12, which can occasionally lead to clinically significant deficiency manifesting as megaloblastic anemia or peripheral neuropathy. Patients taking Icandra for prolonged periods should have their vitamin B12 levels checked periodically, particularly if they develop symptoms suggestive of anemia or neuropathy.

How Should You Store Icandra?

Proper storage of Icandra ensures that the tablets retain their quality, safety, and effectiveness throughout the shelf life. As a solid oral dosage form (film-coated tablet), Icandra is generally stable under normal conditions, but certain environmental factors can compromise the medication.

Follow these storage guidelines carefully:

• Temperature: Store below 30°C (86°F). Avoid exposure to extreme heat. Do not store in direct sunlight or near heat sources such as radiators, stoves, or car dashboards, especially during summer months.
• Moisture protection: Keep the tablets in the original blister pack or container to protect from moisture and humidity. Do not transfer tablets to pill organizers for extended periods unless the organizer is kept in a dry environment. Excessive humidity can degrade the active ingredients.
• Expiration date: Do not use Icandra after the expiration date printed on the blister pack and outer carton after “EXP.” The expiration date refers to the last day of that month. Expired medications may have reduced potency or altered chemical composition.
• Keep out of reach of children: Store Icandra in a safe, secure location where children cannot access it. Accidental ingestion by a child could cause serious hypoglycemia, especially if the child does not have diabetes.
• Disposal: Do not throw away unused or expired tablets in household waste or flush them down the toilet. Return unused medication to your pharmacist for safe disposal according to local regulations. Proper disposal helps protect the environment from pharmaceutical contamination.

When traveling with Icandra, keep the medication in your carry-on luggage to avoid temperature extremes in the cargo hold. Carry the tablets in their original packaging, which includes the product name, strength, and expiration date, and bring a copy of your prescription or a letter from your doctor confirming your need for the medication, especially when traveling internationally.

What Does Icandra Contain?

Understanding the composition of your medication is important, particularly if you have known allergies or sensitivities to specific ingredients. Below is a detailed breakdown of the contents of Icandra film-coated tablets.

Active Ingredients

Each film-coated tablet of Icandra contains:

• Vildagliptin: 50 mg – A selective, reversible DPP-4 inhibitor that enhances the incretin system to improve glucose-dependent insulin secretion and reduce inappropriate glucagon release.
• Metformin hydrochloride: 850 mg (corresponding to approximately 660 mg of metformin base) – A biguanide antidiabetic that reduces hepatic glucose production, decreases intestinal glucose absorption, and improves peripheral insulin sensitivity.

Inactive Ingredients (Excipients)

Icandra tablets are available as film-coated tablets with a yellow color and a characteristic shape and markings for identification. Each tablet is imprinted with a code to help distinguish it from other medications. The film coating protects the active ingredients from moisture and light and also makes the tablet easier to swallow.

Icandra does not contain gluten, lactose, or animal-derived gelatin. However, if you have specific allergies or dietary restrictions related to any of the excipients listed above, consult your pharmacist or doctor before starting treatment.